NEET PG – 84292

Neelam Maurya

7 years ago

Which of the following anticancer drugs are competitive inhibitors of tyrosine kinase –

A. Imatinib and sunitinib

B. Letrozole

C. Bicalutamide

D. Fulvestrant

Show Answer

Correct Answer » A

Explanation

Ans. is ‘a’ i.e., Imatinib and sunitinib

Molecular targeted agents

Tyrosine kinase inhibitors

Competitive inhibitors → Imatinib, Nilotinib, Sunitinib, Dasatinib, Erlotinib, Gefitinib, Lapatinib, Sorafenib (Remember all end with ‘ nib’).

Monoclonal antibodies → Cetuximab, panitumumab.

HER₂/neu (ERB B₂) inhibitors Monoclonal antibody – Trastuzumab.

Targeted antibody → Gemtuzumab (anti CD-33), Rituximab (anti – CD20), Alemtuzumab (anti CD-52).

Vascular endothelial growth factor (VEGF) inhibitor → Monoclonal antibody – Bevacizumab.

Proteosome inhibitors → Bortezomib.

Histone deacetylase inhibitor → Vorinostat

DNA – methyltransferase inhibitor → 5-azacytidine, 2-deoxy-5 azacytidine

All – trans-retinoic acid.

Biological response modifier – Recombinant IL-2 (aldesleukin, denileukin)